Search the Newsreel

ETFs Investing in Corcept Therapeutics Incorporated. Stocks

This article lists various ETFs that include Corcept Therapeutics Incorporated. (HTD) stocks in their holdings. The ETFs are sorted by market value and provide details such as weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total …

Corteva, Inc. (CTVA) Upgraded to Buy: Here's What You Should Know

Corteva, Inc. (CTVA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant …

Corteva Set to Report Q2 Earnings: What Investors Should Expect

Corteva, Inc. CTVA is likely to witness growth in its top and bottom lines when it reports second-quarter fiscal 2026 results on July 30, after the opening bell. The Zacks Consensus Estimate for quarterly revenues is pegged at $6.61 billion, indicating a 2.4% dip …

Corteva (CTVA) Dividend Reaffirmed As Earnings Beat Hopes Keep Valuation In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Dividend affirmation and earnings expectations set the tone Corteva (CTVA) has reaffirmed a common stock dividend of $0.18 per share, payable on September …

Corteva Keeps Quarterly Dividend at $0.18 a Share, Payable Sept. 15 to Holders of Record Sept. 1

Corteva, Inc. announced its quarterly dividend will remain at $0.18 per share. The dividend is payable on September 15, 2026, to shareholders of record as of September 1, 2026. This information was officially released by MT Newswires.

Corteva declares $0.18 quarterly dividend per share

Corteva Inc. (NYSE:CTVA) announced a quarterly common stock dividend of $0.18 per share, payable on September 15, 2026, to shareholders of record as of September 1, 2026. Additionally, the Board of Directors of EIDP Inc., a Corteva subsidiary, declared preferred stock dividends of $1.125 …

Corteva Subsidiary EIDP Declares Two Preferred Dividends

Corteva, Inc. (NYSE: CTVA) announced a common stock dividend of $0.18 per share, payable on September 15, 2026, to shareholders of record as of September 1, 2026. Separately, EIDP, a wholly-owned subsidiary of Corteva, declared regular preferred dividends on its $4.50 and $3.50 series, …

Corteva Declares Quarterly Dividend

INDIANAPOLIS, July 24, 2026 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) today announced its Board of Directors has authorized a common stock dividend of $0.18 cents per share, payable September 15, 2026, to the Company's shareholders of record on September 1, 2026. EIDP, Inc. Announces …

Corteva (CTVA) Stock Looks Like A Bargain On Cash Flow, Priced For Perfection On Earnings

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Corteva stock has more than doubled over the past five years, yet its valuation signals are pulling in different directions, with a Discounted Cash Flow (DCF) intrinsic …

Sei Investments Co. Boosts Position in Corteva, Inc. $CTVA

Sei Investments Co. increased its stake in Corteva, Inc. (NYSE:CTVA) by 2.9% in the first quarter, now owning 1,572,931 shares valued at approximately $131.67 million. Other institutional investors also adjusted their positions in the agricultural company, which reported strong quarterly earnings and announced a …

Does Rising Confidence In a 2026 Earnings Beat Change The Bull Case For Corteva (CTVA)?

Corteva, Inc. recently drew increased analyst attention as expectations rose that its June 2026 quarter would exceed prior earnings forecasts on higher revenues. Analysts are highlighting Corteva's history of topping consensus earnings estimates and a positive Earnings ESP, which together are fueling confidence ahead …

Corcept Therapeutics Inc (CORT) Fundamental & Financial Data

This article provides fundamental and financial data for Corcept Therapeutics Inc (CORT), including its stock performance, market capitalization, dividend yield, and P/E ratio. It also lists recent news articles related to CORT and popular discussions about other stocks like HIMS and SPY.

CORT: Corcept Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This page provides the latest stock information for Corcept Therapeutics Inc (CORT), including its current stock price, market capitalization, volume, and key financial metrics. It also features recent news articles related to CORT and highlights top discussions among investors regarding other trending stocks like …

CTVA Maintained by Oppenheimer -- Price Target Raised to $95.00

Oppenheimer has maintained an Outperform rating for Corteva (CTVA) and raised its price target to $95.00 from $89.00, reflecting confidence in the company's growth potential. Despite this positive analyst sentiment, GuruFocus indicates that CTVA is currently overvalued with a GF Value™ of $64.80 compared …

Corteva (NYSE:CTVA) Price Target Raised to $95.00

Oppenheimer raised Corteva's (NYSE:CTVA) price target to $95.00 from $89.00, maintaining an "outperform" rating and suggesting a 7.6% upside. This follows strong Q1 results where Corteva beat EPS and revenue estimates. Several other firms have also increased their price targets, leading to a consensus …

Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT) been one of those stocks this year? By taking a look at the stock's year-to-date performance in …

Oppenheimer Adjusts Corteva Price Target to $95 From $89, Maintains Outperform Rating

Oppenheimer has increased its price target for Corteva (CTVA) to $95 from $89, reiterating an Outperform rating on the stock. This adjustment reflects analyst confidence in the agricultural chemicals company. Other recent analyst actions also show upward revisions to Corteva's price targets.

Corcept Therapeutics And 2 Other Growth Stocks With Significant Insider Ownership

This article highlights growth companies in the United States with significant insider ownership, which often indicates strong internal confidence. It specifically discusses Corcept Therapeutics (CORT), Strive (ASST), and Precigen (PGEN), detailing their growth ratings, operational overviews, insider ownership percentages, and future prospects. While these …

Corteva (NYSE:CTVA) Reaches New 12-Month High - Still a Buy?

Corteva (NYSE:CTVA) recently achieved a new 52-week high, trading up to $88.57, reflecting positive analyst sentiment and strong financial performance. The company surpassed earnings expectations with $1.50 EPS and $4.91 billion in revenue, and analysts maintain a "Moderate Buy" consensus with an average price …

Allspring Global Investments Holdings LLC Raises Stock Holdings in Corteva, Inc. $CTVA

Allspring Global Investments Holdings LLC significantly increased its stake in Corteva, Inc. (NYSE:CTVA) by 93.0% during the first quarter, now holding 133,526 shares valued at $11.19 million. Several other hedge funds also modified their positions in Corteva. The article details Corteva's recent financial performance, …

ABN Amro Investment Solutions Sells 93,474 Shares of Corteva, Inc. $CTVA

ABN Amro Investment Solutions significantly reduced its stake in Corteva, Inc. (NYSE:CTVA) by 59.4% in Q1, selling 93,474 shares and retaining 63,821 shares valued at approximately $5.34 million. Despite this sale, Wall Street analysts maintain a positive outlook, with a consensus "Moderate Buy" rating …

Corteva, Inc. (CTVA) Earnings Expected to Grow: Should You Buy?

Corteva (CTVA) Projected to Post Quarterly Earnings on Thursday

Corteva (CTVA) is expected to announce its Q2 2026 earnings on Thursday, July 30th, with analysts projecting $2.23 EPS on $6.593 billion in revenue. The company recently exceeded expectations in its last quarterly report, posting $1.50 EPS against an estimated $1.18, and saw an …

Corcept Therapeutics to announce Q2 results on July 29

Corcept Therapeutics will release its second quarter financial results and provide a corporate update on July 29, 2026. This announcement will be followed by a conference call at 5:00 p.m. ET to discuss the results and business developments. The company, known for its work …

Corcept Sets July 29 Results Call for 5 p.m. Eastern

Corcept Therapeutics Incorporated (NASDAQ: CORT) announced it will report second-quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call at 5:00 p.m. Eastern Time on the same day. Participants must register in advance for …

RBC Raises Price Target on Corteva to $103 From $97, Keeps Outperform Rating

RBC Capital Markets has increased its price target for Corteva (NYSE: CTVA) to $103 from $97, while maintaining an Outperform rating on the stock. This revised target suggests a positive outlook for the agricultural science company, with RBC analysts anticipating continued strong performance.

Corteva Inc. stock underperforms Wednesday when compared to competitors despite daily gains

On Wednesday, Corteva Inc. (CTVA) stock saw a 1.83% increase, closing at $88.53. Despite these daily gains, the stock underperformed compared to its competitors, happening on a generally negative trading day where the S&P 500 and Dow Jones Industrial Average both experienced slight declines. …

Will Corteva, Inc. (CTVA) Beat Estimates Again in Its Next Earnings Report?

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Corteva, Inc. (CTVA). This company, which is in the Zacks …

Dimensional Fund Advisors LP Acquires 78,994 Shares of Corteva, Inc. $CTVA

Dimensional Fund Advisors LP increased its stake in Corteva, Inc. (NYSE:CTVA) by 1.7%, purchasing 78,994 additional shares and bringing its total holdings to 4.77 million shares valued at approximately $399.4 million. Wall Street analysts maintain a "Moderate Buy" consensus rating for Corteva with an …

Trump Disclosure Shows Corcept Buy Before FDA Approval

A public financial disclosure by President Donald Trump revealed a purchase of Corcept Therapeutics stock worth $50,001 to $100,000 on March 3rd, 2026. This purchase occurred weeks before the FDA approved Corcept's ovarian-cancer drug Lifyorli on March 25th, potentially impacting the stock's value. The …

Escorts Kubota to discuss Q1FY27 earnings on August 3

Corcept Therapeutics stock hits 52-week high at 95.18 USD By Investing.com

Corcept Therapeutics (CORT) stock has climbed to a new 52-week high of $95.18, showcasing a 152% return over the past six months and a 163% year-to-date gain, reflecting strong investor confidence and strategic advancements. Despite an InvestingPro analysis indicating the stock might be overvalued …

Mediolanum International Funds Ltd Has $6.17 Million Stock Holdings in Corteva, Inc. $CTVA

Mediolanum International Funds Ltd significantly cut its stake in Corteva (NYSE:CTVA) by 48.5% in the first quarter, now holding 74,337 shares valued at $6.17 million. Despite this reduction, other institutional investors increased their positions, and 81.54% of the stock is held by institutional investors. …

184,568 Shares in Corteva, Inc. $CTVA Purchased by SEB Asset Management AB

SEB Asset Management AB has acquired a new stake of 184,568 shares in Corteva, Inc. (NYSE:CTVA) during the first quarter, valued at approximately $15.45 million. Other institutional investors like Harris Associates L P, Norges Bank, and Northwestern Mutual Wealth Management Co. have also significantly …

Corteva, Inc. $CTVA Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. reduced its stake in Corteva (NYSE:CTVA) by 6.2% in the first quarter, selling 18,258 shares. However, other institutional investors like Vanguard Group Inc., State Street Corp, Franklin Resources Inc., Harris Associates L P, and Northern Trust Corp significantly increased …

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

Key Points The transaction involved 40,000 shares with an estimated value of $3.5 million on the July 15, 2026 transaction date. The activity was executed through the conversion of 40,000 options at $19.26 and $23.06 per share, which were immediately liquidated. The transaction was …